Jenny Shan, MD, Ph.DChief Scientific Officer at Cyagen BiosciencesSpeaker
Profile
Jenny holds an MD and a PhD in Cancer Biology from Columbia University. She has supported numerous internally developed and externally licensed biologics programs from discovery through IND and regulatory approval, including blockbuster therapies Eylea, Dupixent, Carvykti, and Rybrevant.
Jenny Currently is the Chief Scientific Officer at Cyagen, where she evaluates innovative technology platforms and preclinical and early clinical biologics assets spanning immunology, oncology, and metabolism.
Agenda Sessions
HUGO-Nano: A Human VHH Mouse Platform Engineered with Camelid Features
, 9:50amView Session
